Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al

J Immunother Cancer. 2022 Jan;10(1):e004347. doi: 10.1136/jitc-2021-004347.
No abstract available

Keywords: adjuvants; immunologic; immunotherapy; melanoma; programmed cell death 1 receptor.

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Melanoma*
  • Skin Neoplasms*